Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity
Tito Fojo(National Institutes of Health), Andrew W. Lo, Sham Mailankody(Memorial Sloan Kettering Cancer Center)
Cited by 301
Related Papers
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
|New England Journal of Medicine|2012|863
Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval
|JAMA Internal Medicine|2017|497
The high price of anticancer drugs: origins, implications, barriers, solutions
|Nature Reviews Clinical Oncology|2017|430
GPRC5D-Targeted CAR T Cells for Myeloma
|New England Journal of Medicine|2022|383